# Top 10 outcome extracts from lung_EN_cleaned.json

=== Ranked Outcome 1 (Extract #3, Effect) — Score: 3 ===
care
to support people and (as appropriate) their family members or carers. [2011]
1.2.3 Offer accurate and easy-to-understand information to people and their family
members or carers (as appropriate). Explain the tests and treatment options,
including potential survival benefits, side effects and effect on symptoms. [2011]
1.2.4 Consider tailor-made decision aids to help people to:
• understand the probable outcomes of treatment options
• think about the personal value they place on benefits versus harms of
treatment options
• feel supported in decision making
• move through the steps towards maki

=== Ranked Outcome 2 (Extract #1, Result) — Score: 2 ===
re between their scheduled hospital visits. [2011]
1.22.4 The opinions and experiences of people with lung cancer and their family
members or carers (as appropriate) should be collected and used to improve the
delivery of lung cancer services. People should receive feedback on any action
taken as a result of such surveys. [2005]
© NICE 2024. All rights reserved. Subject to Notice of rights  Page 34 The guideline committee has made the following recommendations for research. What is the effectiveness and cost effectiveness of immunotherapy in people with
stage IIIA-N2 non-small-cell lung cancer follo

=== Ranked Outcome 3 (Extract #2, Result) — Score: 2 ===
TBNA) and subsequent investigations.
The word 'fibreoptic' has been removed because bronchoscopy can be fibreoptic, video or
hybrid. The recommendations on PET-CT reflect current practice, so will not incur an extra cost.
The recommendations on EBUS-TBNA and EUS-FNA will reinforce best practice and result
in a more streamlined diagnostic service with more timely diagnosis and staging.
The surgical mediastinal staging recommendation will also reinforce best practice and
restrict this procedure to people most likely to benefit.
Return to recommendations
© NICE 2024. All rights reserved. Subject to Not

